Nanomedicine: current status and future prospects

Poole C. P., 2003, Introduction to Nanotechnology

10.1038/nbt0396-303

10.1021/ja0102639

10.1161/01.RES.0000119321.18573.5A

10.1002/cbic.200300730

10.1093/brain/awh191

Dousset V., 1999, Comparison of ultrasmall particles of iron oxide (USIOP) -enhanced T2-weighted, conventional T2-weighted, and gadolinium-enhanced T1-weighted MR images in rats with experimental autoimmune encephalomyelitis, Am. J. Neuroradiol., 20, 223

10.1056/NEJMoa022749

10.1016/S0730-725X(01)00448-9

10.1161/01.CIR.103.3.415

10.1161/01.CIR.0000068315.98705.CC

10.2144/03342bi01

10.1016/S0958-1669(02)00282-3

10.1038/nbt767

10.1126/science.1083780

10.1126/science.1077194

10.1021/bc034153y

10.1038/nbt994

10.1073/pnas.152463399

10.1038/nm1096

10.1126/science.1088525

10.1038/nbt764

10.1126/science.1095833

Moghimi S. M., 2001, Long-circulating and target-specific nanoparticles: theory to practice, Pharmacol. Rev., 53, 283

10.1016/S1359-6446(03)02903-9

Panyam J., 2004, Biodegradable nanoparticles for drug and gene delivery to cells and tissues, Adv. Drug Deliv. Rev., 55, 329, 10.1016/S0169-409X(02)00228-4

10.1016/j.jconrel.2003.10.018

10.1002/jps.10397

10.1021/nl025604a

10.1021/ja0347383

10.1002/cbic.200300905

10.1002/anie.200301694

10.1016/0168-3659(95)00169-7

10.1016/S1471-4914(03)00005-4

10.1021/bm025740

Fenske D. B., 2001, Long-circulating vectors for the systemic delivery of genes, Curr. Opin. Mol. Therap., 3, 153

10.1021/jm9911579

10.1038/nrd1494

10.1016/0378-5173(95)00122-Y

10.1038/nrc903

10.1016/S0169-409X(99)00062-9

10.1073/pnas.0931428100

10.1016/S0163-7827(00)00011-4

10.1096/fj.02-0088com

10.1021/ac990629o

10.1023/A:1020398624602

10.1016/S0163-7827(03)00033-X

10.1023/A:1011054123304

10.1016/S1567-5769(01)00006-6

10.1038/nbt920

10.1016/S0167-4889(02)00204-5

10.1016/S0014-5793(02)03710-9

10.1002/hep.1840210130

10.1016/S1359-6446(03)02686-2

10.1126/science.289.5482.1197

10.1038/nm0202-121

10.1073/pnas.1434429100

10.1016/S1471-4914(02)02429-2

10.1038/nature02580

10.1016/S1359-6446(02)02501-1

Murray J. C., 2003, Endothelial cells as therapeutic targets in cancer: new biology and novel delivery systems, Crit. Rev. Ther. Drug Carrier Syst., 20, 139, 10.1615/CritRevTherDrugCarrierSyst.v20.i23.20

10.1016/S0169-409X(98)00099-4

Phillips W. T., 2000, Novel method of greatly enhanced delivery of liposomes to lymph nodes, J. Pharmacol. Exp. Ther., 295, 309

10.1016/S0014-5793(03)00273-4

10.1358/dot.2004.40.2.799425

10.1023/A:1015127225021

10.1016/S0169-409X(99)00061-7

10.1038/sj.bmt.1704408

10.1080/13693780310001624583

10.1002/1529-0131(200009)43:9<1951::AID-ANR5>3.0.CO;2-K

10.1016/S0304-3959(99)00306-1

10.1034/j.1399-3089.2000.00071.x

10.1097/00005344-200311000-00014

Wolf G., 1997, Enhancement of in vivo adenovirus-mediated gene transfer and expression by prior depletion of tissue macrophages in the target organ, J. Virol., 71, 624, 10.1128/JVI.71.1.624-629.1997

10.1182/blood.V96.8.2834

10.1038/nature02405

10.1038/15058

10.1016/S1525-0016(03)00064-9

10.1016/S0264-410X(02)00512-1

10.1615/CritRevTherDrugCarrierSyst.v20.i23.10

10.1038/nmat974

10.1002/1521-4141(200006)30:6<1714::AID-IMMU1714>3.0.CO;2-C

10.1073/pnas.0308490100

10.1189/jlb.0104031

10.1038/nm1039

10.1002/jmr.650

10.1084/jem.20021598

10.1016/0014-5793(92)80655-Z

10.1023/A:1022604120952

10.1002/ijc.20048

McLean J. W., 1997, Organ-specific endothelial uptake of cationic liposome-DNA complexes in mice, Am. J. Physiol., 273, H387

10.1172/JCI6869

10.1016/S0002-9440(10)65005-5

10.1021/bi002101f

10.1126/science.279.5349.377

Zitzmann S., 2002, Arginine-glycine-aspartic acid (RGD)-peptide binds to both tumor and tumor-endothelial cells in vivo, Cancer Res., 62, 5139

10.1038/sj.gt.3301115

Haviv Y. S., 2002, Adenoviral gene therapy for renal cancer requires retargeting to alternative cellular receptors, Cancer Res., 62, 4273

10.1006/mthe.2002.0668

Curnis F., 2000, Improving chemotherapeutic drug penetration in tumours by vascular targeting and barrier alteration, J. Clin. Invest., 110, 475, 10.1172/JCI0215223

10.1038/nm720

10.1038/nm1101-1194

10.1126/science.1070200

Winter P. M., 2003, Molecular imaging of angiogenesis in nascent vx-2 rabbit tumours using a novel alpha(v)beta(3)-targeted nanoparticle and 1.5 tesla magnetic resonance imaging, Cancer Res., 63, 5838

Pastorino F., 2003, Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy, Cancer Res., 63, 7400

10.1152/ajpcell.00099.2003

10.1073/pnas.96.5.2379

Christofidou-Solomidou M., 2000, Immunotargeting of glucose oxidase to endothelium in vivo causes oxidative vascular injury in the lungs, Am. J. Physiol., 278, L794

Scherpereel A., 2001, Cell-selective intracellular delivery of a foreign enzyme to endothelium in vivo using vascular immunotargeting, FASEB J., 15, 416, 10.1096/fj.00-0022com

Ran S., 1998, Infarction of solid Hodgkin's tumors in mice by antibody-directed targeting of tissue factor to tumour vasculature, Cancer Res., 58, 4646

Drummond D. C., 1999, Optimizing liposomes for delivery of chemotherapeutic agents to solid tumours, Pharmacol. Rev., 51, 691

10.1161/01.RES.0000069021.56380.E2

10.1136/ard.2003.009944

10.1016/S0168-3659(03)00217-7

10.1016/S0168-3659(01)00306-6

10.1038/427695a

10.1073/pnas.081626898

10.2165/00003088-200342050-00002

10.1016/S1359-0294(00)00090-X

Banadak S., 1999, Pharmacological studies of cisplatin encapsulated in long-circulating liposomes in mouse tumor models, Anticancer Drugs, 10, 911, 10.1097/00001813-199911000-00007

Davidson J., 2003, Secereted phospholipase A2 as a new enzymatic trigger mechanism for localised liposomal drug release and absorption in diseased tissue, Biochim. Biophys. Acta, 1609, 95, 10.1016/S0005-2736(02)00659-4

10.1016/S0014-5793(02)03408-7

Davidson J., 2002, Synergistic permeability enhancing effect of lysophospholipids and fatty acids on lipid membranes, Biochim. Biophys. Acta, 1564, 256, 10.1016/S0005-2736(02)00461-3

10.1021/jm031029r

McIntyre J. O., 2004, Development of a novel fluorogenic proteolytic beacon for in vivo detection and imaging of tumour-associated matrix metalloproteinase-7 activity, Biochem. J., 377, 617, 10.1042/bj20030582

Sapra P., 2002, Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs, Cancer Res., 62, 7190

Goren D., 2000, Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump, Clin. Cancer Res., 6, 1949

10.1002/j.1460-2075.1991.tb07697.x

10.1073/pnas.0435906100

10.1074/jbc.M209548200

10.1038/nm996

Panyam J., 2003, Sustained cytoplasmic delivery of drugs with intracellular receptors using biodegradable nanoparticles, Mol. Pharmaceut., 1, 77, 10.1021/mp034002c

10.2174/0929867033457412

10.1002/jgm.507

10.4049/jimmunol.173.4.2578

10.1021/mp034021m

10.1038/nbt875

10.1016/S1359-6446(02)02444-3

10.1080/713853956

10.1021/nl0347334

10.1126/science.1078192

10.1126/science.303.5658.626

10.1021/bc025555t

10.1002/jbm.820271214

10.1124/jpet.102.043307

10.1038/85115

10.1016/S0168-3659(03)00211-6

10.1038/nature02388

10.1126/science.1093783

10.1038/nbt981

10.1038/35038533

10.1038/427779a

10.1016/j.jconrel.2004.02.011

Murray J. C., 2004, Lymphocyte death by cationic polymers: A role for mitochondrion and implications in gene therapy, Br. J. Cancer, 91, S75

10.1080/10611860310001636908

10.1021/ja016288p

10.1002/anie.200351244

10.1615/CritRevTherDrugCarrierSyst.v18.i6.50

10.1016/j.bbadis.2004.02.005

10.1093/annonc/mdg374

La Van D. A., 2002, Moving smaller in drug discovery and delivery, Nat. Rev. Drug Discov., 1, 77, 10.1038/nrd707